BTI 322

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBTI 322
Drug Alias NameLo-CD2-aAnti-CD2 monoclonal antibodyMonoclonal antibody Lo-CD2-aBTI-322
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT-cell surface antigen CD2 inhibitors
TargetsT-cell surface antigen CD2
Therapy Area/IndicationsRejection of renal transplantationGraft vs Host DiseaseAutoimmune Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Leuven
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of LeuvenMedimmune Llc
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationGraft vs Host DiseaseAutoimmune Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A